ArriVent Phase 3 data show firmonertinib misses primary PFS endpoint vs chemo in lung cancer

 

ArriVent detailed Phase 3 FURVENT data show firmonertinib misses primary PFS endpoint vs chemotherapy in EGFR exon 20 NSCLC (HR 0.75; p=0.0654)

• FURVENT evaluated firmonertinib as first-line treatment for EGFR exon 20 insertion-mutant non-small cell lung cancer
• Company is evaluating the full Phase 3 dataset to determine firmonertinib’s future development path

https://finviz.com/stock?t=AVBP&p=d